Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2060 PK/PD in Chronic and End-Stage Kidney Disease
NCT05656040Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic kidney disease (CKD) and end stage renal disease (ESRD) comparing MK-2060 Arm with Placebo Arm (2 arms). Primary endpoints: Number of Participants Who Experience One or More Bleeding Related Adverse Events up to 144 days, Number of Participants Who Experience One or More Adverse Events up to 144 days and 9 more. Started Feb 2023; status: completed.
02
Drugs
MK-2060
03
Conditions
chronic kidney disease (CKD)end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT05656040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05656040.